Navigation Links
Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Date:12/1/2008

BASKING RIDGE, N.J., Dec. 1 /PRNewswire/ -- Regado Biosciences, Inc., announced today David J. Mazzo, Ph.D., President and Chief Executive Officer, will present at the 20th Annual Piper Jaffray Health Care Conference in New York, NY, on Tuesday, December 2, 2008, at 10:10am (Eastern Standard Time). Dr. Mazzo will discuss the Company's development pipeline, in addition to reviewing recent business and clinical developments.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the creation and development of two-component drug systems, comprising an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect. Enhanced control and flexibility allow physicians to meet the individual needs of patients independent of the setting. Regado is focusing its discovery and development efforts on acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control.

Current investors in Regado include Domain (Princeton, NJ), Quaker BioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton Advantage Life Sciences Fund (New York, NY), as well as individual investors, including Robert Kierlin.


'/>"/>
SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
2. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
3. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
4. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
5. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
6. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
7. BBM Announces Offer to Acquire YM BioSciences Inc.
8. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
9. LI-COR Biosciences and Mandel Scientific Company Inc. Announce Distribution Agreement
10. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
11. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... the international society for optics and photonics , have been named Fellows of ... individual’s significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, ...
Breaking Biology Technology:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):